Jiahao Mei

Jiahao Mei

Auto-generated profile, based on publicly available information

Jiahao Mei

College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ZHZe Hong
Ze Hong
JMJiahao Mei
Jiahao Mei
CLChenhui Li
Chenhui Li
GBGuohui Bai
Guohui Bai
MMMunire Maimaiti
Munire Maimaiti
CWChen Wang
Chen Wang
Cytosolic DNA activates cGAS (cytosolic DNA sensor cyclic AMP-GMP synthase)-STING (stimulator of interferon genes) signaling, which triggers interferon and inflammatory responses that help defend against microbial infection and cancer. However, aberrant cytosolic self-DNA in Aicardi–Goutière’s syndrome and constituently active gain-of-function mutations in STING in STING-associated vasculopathy with onset in infancy (SAVI) patients lead to excessive type I interferons and proinflammatory cytokines, which cause difficult-to-treat and sometimes fatal autoimmune disease. Here, in silico docking identified a potent STING antagonist SN-011 that binds with higher affinity to the cyclic dinucleotide (CDN)-binding pocket of STING than endogenous 2′3′-cGAMP. SN-011 locks STING in an open inactive conformation, which inhibits interferon and inflammatory cytokine induction activated by 2′3′-cGAMP, herpes simplex virus type 1 infection, Trex1 deficiency, overexpression of cGAS-STING, or SAVI STING mutants. In Trex1−/− mice, SN-011 was well tolerated, strongly inhibited hallmarks of inflammation and autoimmunity disease, and prevented death. Thus, a specific STING inhibitor that binds to the STING CDN-binding pocket is a promising lead compound for STING-driven disease. Significance cGAS (cytosolic DNA sensor cyclic AMP-GMP synthase)-STING (stimulator of interferon genes) signaling is critical for sensing cytosolic DNA to initiate host immune responses against invading pathogens and cancer. However, inappropriate activation of STING signaling causes severe and often fatal autoimmune or autoinflammatory diseases. Hence, STING is an attractive drug target for the treatment of STING-driven autoimmune and inflammatory disorders. Therefore, there is a need to identify lead compounds that effectively inhibit human STING for further drug development. Here, we identified and characterized a STING-specific inhibitor SN-011 with high efficiency, specificity, and safety, paving the way for therapeutically manipulating STING-mediated clinical diseases.

28 May 2026 in Science
Verified
Journal Article
Closed access
QFQiongxuan Fan
Qiongxuan Fan
JMJiahao Mei
Jiahao Mei
TLTian Li
Tian Li
CZChuanlong Zang
Chuanlong Zang
MLMengjiao Li
Mengjiao Li
BDBobo Dang
Bobo Dang
Covalent protein drugs offer therapeutic potential but are limited by slow target engagement and the absence of high-throughput selection platforms. Rapid covalent binding requires coordinated optimization of affinity, stability, and warhead geometry, which is an intrinsically multidimensional challenge. We developed a yeast display platform coupled with chemoselective modification that enables selection of fast-acting covalent proteins without increasing intrinsic warhead reactivity. Using this system, we engineered a covalent programmed death-ligand 1 (PD-L1) antagonistic nanobody with rapid cross-linking kinetics [observed rate constant ( k obs ) = 0.18 min −1 , half-life ( t 1/2 ) = 3.8 min] and improved tumor suppression compared with envafolimab and atezolizumab. Similarly, we engineered a fast-acting covalent interleukin-18 ( k obs = 0.54 min −1 , t 1/2 = 1.3 min) and a covalent miniprotein targeting the receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), demonstrating applicability across protein modalities.